Induction of leukocyte infiltration at metastatic site mediates the protective effect of NGcGM3-based vaccine

References

• Hakomori S, Young WW Jr., Patt LM, Yoshino T, Halfpap L, Lingwood CA. Cell biological and immunological significance of ganglioside changes associated with transformation. Adv Exp Med Biol 1980; 125:247 - 61; http://dx.doi.org/10.1007/978-1-4684-7844-0_24; PMID: 6244722
   PubMedGoogle Scholar
• Livingston PO, Hood C, Krug LM, Warren N, Kris MG, Brezicka T, Ragupathi G. Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy. Cancer Immunol Immunother 2005; 54:1018 - 25; http://dx.doi.org/10.1007/s00262-005-0663-8; PMID: 15926079
   PubMed Web of Science ®Google Scholar
• Birklé S, Zeng G, Gao L, Yu RK, Aubry J. Role of tumor-associated gangliosides in cancer progression. Biochimie 2003; 85:455 - 63; http://dx.doi.org/10.1016/S0300-9084(03)00006-3; PMID: 12770784
   PubMed Web of Science ®Google Scholar
• Choi HJ, Chung TW, Kang SK, Lee YC, Ko JH, Kim JG, Kim CH. Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression--transcriptional induction of p21(WAF1) and p27(kip1) by inhibition of PI-3K/AKT pathway. Glycobiology 2006; 16:573 - 83; http://dx.doi.org/10.1093/glycob/cwj105; PMID: 16574813
   PubMed Web of Science ®Google Scholar
• Ferrone S. Changes in serum ganglioside and antibody levels in soft tissue sarcoma: are they the cause or the effect of tumor progression?. Cancer J 2002; 8:369 - 70; http://dx.doi.org/10.1097/00130404-200209000-00006; PMID: 12416893
   PubMed Web of Science ®Google Scholar
• Alessandri G, Filippeschi S, Sinibaldi P, Mornet F, Passera P, Spreafico F, Cappa PM, Gullino PM. Influence of gangliosides on primary and metastatic neoplastic growth in human and murine cells. Cancer Res 1987; 47:4243 - 7; PMID: 2440560
   PubMed Web of Science ®Google Scholar
• Ladisch S, Kitada S, Hays EF. Gangliosides shed by tumor cells enhance tumor formation in mice. J Clin Invest 1987; 79:1879 - 82; http://dx.doi.org/10.1172/JCI113031; PMID: 3584474
   PubMed Web of Science ®Google Scholar
• Ladisch S. Tumor cell gangliosides. Adv Pediatr 1987; 34:45 - 58; PMID: 3318303
   PubMedGoogle Scholar
• Fernandez LE, Gabri MR, Guthmann MD, Gomez RE, Gold S, Fainboim L, Gomez DE, Alonso DF. NGcGM3 ganglioside: a privileged target for cancer vaccines. Clin Dev Immunol 2010; 2010:814397; http://dx.doi.org/10.1155/2010/814397; PMID: 21048926
   PubMedGoogle Scholar
• de Leòn J, Fernández A, Mesa C, Clavel M, Fernández LE. Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells. Cancer Immunol Immunother 2006; 55:443 - 50; http://dx.doi.org/10.1007/s00262-005-0041-6; PMID: 16208470
   PubMed Web of Science ®Google Scholar
• de León J, Fernández A, Clavell M, Labrada M, Bebelagua Y, Mesa C, Fernández LE. Differential influence of the tumour-specific non-human sialic acid containing GM3 ganglioside on CD4+CD25- effector and naturally occurring CD4+CD25+ regulatory T cells function. Int Immunol 2008; 20:591 - 600; http://dx.doi.org/10.1093/intimm/dxn018; PMID: 18310617
   PubMed Web of Science ®Google Scholar
• Osorio M, Gracia E, Rodríguez E, Saurez G, Arango MdelC, Noris E, Torriella A, Joan A, Gómez E, Anasagasti L, et al. Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: results of a Phase Ib/IIa study. Cancer Biol Ther 2008; 7:488 - 95; http://dx.doi.org/10.4161/cbt.7.4.5476; PMID: 18285705
   PubMed Web of Science ®Google Scholar
• Fernández LE, Alonso DF, Gomez DE, Vázquez AM. Ganglioside-based vaccines and anti-idiotype antibodies for active immunotherapy against cancer. Expert Rev Vaccines 2003; 2:817 - 23; http://dx.doi.org/10.1586/14760584.2.6.817; PMID: 14711364
   PubMedGoogle Scholar
• Osorio M, Gracia E, Reigosa E, Hernandez J, de la Torre A, Saurez G, Perez K, Viada C, Cepeda M, Carr A, et al. Effect of vaccination with N-glycolyl GM3/VSSP vaccine by subcutaneous injection in patients with advanced cutaneous melanoma. Cancer Manag Res 2012; 4:341 - 5; http://dx.doi.org/10.2147/CMAR.S22617; PMID: 23055778
   PubMedGoogle Scholar
• Pérez K, Osorio M, Hernández J, Carr A, Fernández LE. NGcGM3/VSSP vaccine as treatment for melanoma patients. Hum Vaccin Immunother 2013; 9:1237 - 40; http://dx.doi.org/10.4161/hv.24115; PMID: 23442598
   PubMed Web of Science ®Google Scholar
• Carr A, Rodríguez E, Arango MdelC, Camacho R, Osorio M, Gabri M, Carrillo G, Valdés Z, Bebelagua Y, Pérez R, et al. Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine. J Clin Oncol 2003; 21:1015 - 21; http://dx.doi.org/10.1200/JCO.2003.02.124; PMID: 12637465
   PubMed Web of Science ®Google Scholar
• Mulens V, de la Torre A, Marinello P, Rodríguez R, Cardoso J, Díaz R, O’Farrill M, Macias A, Viada C, Saurez G, et al. Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients. Hum Vaccin 2010; 6:6; http://dx.doi.org/10.4161/hv.6.9.12571; PMID: 20855939
   PubMed Web of Science ®Google Scholar
• Estevez F, Carr A, Solorzano L, Valiente O, Mesa C, Barroso O, Sierra GV, Fernandez LE. Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP). Vaccine 1999; 18:190 - 7; http://dx.doi.org/10.1016/S0264-410X(99)00219-4; PMID: 10501249
   PubMed Web of Science ®Google Scholar
• Labrada M, Clavell M, Bebelagua Y, León Jd, Alonso DF, Gabri MR, Veloso RC, Vérez V, Fernández LE. Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy. Expert Opin Biol Ther 2010; 10:153 - 62; http://dx.doi.org/10.1517/14712590903443084; PMID: 20088712
   PubMed Web of Science ®Google Scholar
• Carr A, Mullet A, Mazorra Z, Vázquez AM, Alfonso M, Mesa C, Rengifo E, Pérez R, Fernández LE. A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors. Hybridoma 2000; 19:241 - 7; http://dx.doi.org/10.1089/02724570050109639; PMID: 10952412
   PubMed Web of Science ®Google Scholar
• Helling F, Livingston PO. Ganglioside conjugate vaccines. Immunotherapy against tumors of neuroectodermal origin. Mol Chem Neuropathol 1994; 21:299 - 309; http://dx.doi.org/10.1007/BF02815357; PMID: 8086040
   PubMedGoogle Scholar
• Livingston PO. Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol Rev 1995; 145:147 - 66; http://dx.doi.org/10.1111/j.1600-065X.1995.tb00080.x; PMID: 7590824
   PubMed Web of Science ®Google Scholar
• Ritter G, Boosfeld E, Adluri R, Calves M, Oettgen HF, Old LJ, Livingston P. Antibody response to immunization with ganglioside GD3 and GD3 congeners (lactones, amide and gangliosidol) in patients with malignant melanoma. Int J Cancer 1991; 48:379 - 85; http://dx.doi.org/10.1002/ijc.2910480312; PMID: 2040532
   PubMed Web of Science ®Google Scholar
• Chapman PB, Morrisey D, Panageas KS, Williams L, Lewis JJ, Israel RJ, Hamilton WB, Livingston PO. Vaccination with a bivalent G(M2) and G(D2) ganglioside conjugate vaccine: a trial comparing doses of G(D2)-keyhole limpet hemocyanin. Clin Cancer Res 2000; 6:4658 - 62; PMID: 11156217
   PubMed Web of Science ®Google Scholar
• Chapman PB, Morrissey DM, Panageas KS, Hamilton WB, Zhan C, Destro AN, Williams L, Israel RJ, Livingston PO. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study. Clin Cancer Res 2000; 6:874 - 9; PMID: 10741710
   PubMed Web of Science ®Google Scholar
• Ragupathi G, Livingston PO, Hood C, Gathuru J, Krown SE, Chapman PB, Wolchok JD, Williams LJ, Oldfield RC, Hwu WJ. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res 2003; 9:5214 - 20; PMID: 14614001
   PubMed Web of Science ®Google Scholar
• Steitz J, Brück J, Lenz J, Büchs S, Tüting T. Peripheral CD8+ T cell tolerance against melanocytic self-antigens in the skin is regulated in two steps by CD4+ T cells and local inflammation: implications for the pathophysiology of vitiligo. J Invest Dermatol 2005; 124:144 - 50; http://dx.doi.org/10.1111/j.0022-202X.2004.23538.x; PMID: 15654968
   PubMed Web of Science ®Google Scholar
• Speak AO, Cerundolo V, Platt FM. CD1d presentation of glycolipids. Immunol Cell Biol 2008; 86:588 - 97; http://dx.doi.org/10.1038/icb.2008.42; PMID: 18542099
   PubMed Web of Science ®Google Scholar
• MacDonald HR. Development and selection of NKT cells. Curr Opin Immunol 2002; 14:250 - 4; http://dx.doi.org/10.1016/S0952-7915(02)00329-1; PMID: 11869900
   PubMed Web of Science ®Google Scholar
• Chamilos G, Lewis RE, Hu J, Xiao L, Zal T, Gilliet M, Halder G, Kontoyiannis DP. Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis. Proc Natl Acad Sci U S A 2008; 105:9367 - 72; http://dx.doi.org/10.1073/pnas.0709578105; PMID: 18583479
   PubMed Web of Science ®Google Scholar
• Gilliet M, Lande R. Antimicrobial peptides and self-DNA in autoimmune skin inflammation. Curr Opin Immunol 2008; 20:401 - 7; http://dx.doi.org/10.1016/j.coi.2008.06.008; PMID: 18611439
   PubMed Web of Science ®Google Scholar
• Kmieciak M, Basu D, Payne KK, Toor A, Yacoub A, Wang XY, Smith L, Bear HD, Manjili MH. Activated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic mouse. J Immunol 2011; 187:708 - 17; http://dx.doi.org/10.4049/jimmunol.1100502; PMID: 21670315
   PubMed Web of Science ®Google Scholar
• Katz A, Shulman LM, Revel M, Feldman M, Eisenbach L. Combined therapy with IL-6 and inactivated tumor cells suppresses metastasis in mice bearing 3LL lung carcinomas. Int J Cancer 1993; 53:812 - 8; http://dx.doi.org/10.1002/ijc.2910530518; PMID: 8449606
   PubMed Web of Science ®Google Scholar
• Mesa C, de León J, Rigley K, Fernández LE. Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for dendritic cell activation. Vaccine 2006; 24:Suppl 2 S2 - 42, 3; http://dx.doi.org/10.1016/j.vaccine.2005.08.111; PMID: 16823920
   PubMedGoogle Scholar
• Gilliet M, Cao W, Liu YJ. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol 2008; 8:594 - 606; http://dx.doi.org/10.1038/nri2358; PMID: 18641647
   PubMed Web of Science ®Google Scholar
• Swiecki M, Colonna M. Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol Rev 2010; 234:142 - 62; http://dx.doi.org/10.1111/j.0105-2896.2009.00881.x; PMID: 20193017
   PubMed Web of Science ®Google Scholar
• Vermi W, Soncini M, Melocchi L, Sozzani S, Facchetti F. Plasmacytoid dendritic cells and cancer. J Leukoc Biol 2011; 90:681 - 90; http://dx.doi.org/10.1189/jlb.0411190; PMID: 21730085
   PubMed Web of Science ®Google Scholar
• Moodycliffe AM, Nghiem D, Clydesdale G, Ullrich SE. Immune suppression and skin cancer development: regulation by NKT cells. Nat Immunol 2000; 1:521 - 5; http://dx.doi.org/10.1038/82782; PMID: 11101875
   PubMed Web of Science ®Google Scholar
• Spada FM, Borriello F, Sugita M, Watts GF, Koezuka Y, Porcelli SA. Low expression level but potent antigen presenting function of CD1d on monocyte lineage cells. Eur J Immunol 2000; 30:3468 - 77; http://dx.doi.org/10.1002/1521-4141(2000012)30:12<3468::AID-IMMU3468>3.0.CO;2-C; PMID: 11093166
   PubMed Web of Science ®Google Scholar
• Sköld M, Xiong X, Illarionov PA, Besra GS, Behar SM. Interplay of cytokines and microbial signals in regulation of CD1d expression and NKT cell activation. J Immunol 2005; 175:3584 - 93; http://dx.doi.org/10.4049/jimmunol.175.6.3584; PMID: 16148102
   PubMed Web of Science ®Google Scholar
• Raghuraman G, Geng Y, Wang CR. IFN-beta-mediated up-regulation of CD1d in bacteria-infected APCs. J Immunol 2006; 177:7841 - 8; http://dx.doi.org/10.4049/jimmunol.177.11.7841; PMID: 17114455
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhang S, Cheung NK, Ragupathi G, Livingston PO. Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases. Cancer Res 1998; 58:2844 - 9; PMID: 9661900
   PubMed Web of Science ®Google Scholar
• Mazorra Z, Mesa C, Fernández A, Fernández LE. Immunization with a GM3 ganglioside nanoparticulated vaccine confers an effector CD8(+) T cells-mediated protection against melanoma B16 challenge. Cancer Immunol Immunother 2008; 57:1771 - 80; http://dx.doi.org/10.1007/s00262-008-0503-8; PMID: 18351335
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960 - 4; http://dx.doi.org/10.1126/science.1129139; PMID: 17008531
   PubMed Web of Science ®Google Scholar
• Galon J, Fridman WH, Pagès F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res 2007; 67:1883 - 6; http://dx.doi.org/10.1158/0008-5472.CAN-06-4806; PMID: 17332313
   PubMed Web of Science ®Google Scholar
• Eisenbach L, Hollander N, Greenfeld L, Yakor H, Segal S, Feldman M. The differential expression of H-2K versus H-2D antigens, distinguishing high-metastatic from low-metastatic clones, is correlated with the immunogenic properties of the tumor cells. Int J Cancer 1984; 34:567 - 73; http://dx.doi.org/10.1002/ijc.2910340421; PMID: 6490207
   PubMed Web of Science ®Google Scholar
• Eisenbach L, Segal S, Feldman M. MHC imbalance and metastatic spread in Lewis lung carcinoma clones. Int J Cancer 1983; 32:113 - 20; http://dx.doi.org/10.1002/ijc.2910320118; PMID: 6862690
   PubMed Web of Science ®Google Scholar
• Gorelik E, Segal S, Feldman M. Control of lung metastasis progression in mice: role of growth kinetics of 3LL Lewis lung carcinoma and host immune reactivity. J Natl Cancer Inst 1980; 65:1257 - 64; PMID: 6933271
   PubMed Web of Science ®Google Scholar